Literature DB >> 10762016

Differential expression of genes by tumor cells of a low or a high malignancy phenotype: the case of murine and human Ly-6 proteins.

I P Witz1.   

Abstract

Progression of tumor cells toward a high malignancy phenotype and metastasis is a multi-event cascade involving inter alia alterations in the expression of various genes. The focus of our laboratory is on genes whose altered expression may lead, directly or indirectly, to an increased malignancy phenotype. The identification of such genes and the evaluation of the consequences of their altered expression is essential for attempts to halt tumor progression and prevent metastasis formation. Published work originating in our laboratory showed that members of the murine Ly-6 supergene family are involved in the progression of certain mouse tumors. The expression level of several members of this family was higher on highly malignant cells than on tumor cells expressing a lower malignancy phenotype. Sorting by flow cytometry of tumor cells to subpopulations expressing either high or low levels of Ly-6E.1 yielded correspondingly cells expressing a high or a low malignancy phenotype. The high malignancy, high Ly-6E.1-expressing cells also expressed high levels of the receptor for urokinase plasminogen activator (uPAR), whereas low malignancy, low Ly-6E.1-expressing cells also expressed low levels of uPAR. Transfection studies indicated that uPAR was causally involved in conferring a high malignancy phenotype upon tumor cells expressing high levels of Ly-6E.1. E48 is a human homologue of the murine ThB protein, a member of the Ly-6 supergene family (but distinct from the Ly-6E.1 protein mentioned above) and expressed on head and neck squamous carcinoma cells. Experiments currently in progress are aimed to find out whether E48 is involved in the progression of such cancer cells. Using the differential display technology, it was shown that ligation of E48 on tumor cells by the corresponding antibodies (serving as a surrogate for an as yet unidentified E48 ligand) upregulates an enzyme (FX) involved in the biosynthesis of GDP-L-fucose. Fucose is an essential component of certain selectin ligands.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10762016

Source DB:  PubMed          Journal:  J Cell Biochem Suppl        ISSN: 0733-1959


  9 in total

1.  Growth, regeneration, and tumorigenesis of the prostate activates the PSCA promoter.

Authors:  Tetsuro Watabe; Mark Lin; Hisamitsu Ide; Annemarie A Donjacour; Gerald R Cunha; Owen N Witte; Robert E Reiter
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

2.  Nonadherent culture method downregulates stem cell antigen-1 expression in mouse bone marrow mesenchymal stem cells.

Authors:  Baoping Deng; Weiping Deng; Pingnan Xiao; Kuan Zeng; Shining Zhang; Hongwu Zhang; David Yb Deng; Yanqi Yang
Journal:  Exp Ther Med       Date:  2015-04-29       Impact factor: 2.447

3.  SDF1/CXCL12 is involved in recruitment of stem-like progenitor cells to orthotopic murine malignant mesothelioma spheroids.

Authors:  Bonnie W Lau; Agnes B Kane
Journal:  Anticancer Res       Date:  2010-06       Impact factor: 2.480

4.  Identification of novel peroxisome proliferator-activated receptor alpha (PPARalpha) target genes in mouse liver using cDNA microarray analysis.

Authors:  M Cherkaoui-Malki; K Meyer; W Q Cao; N Latruffe; A V Yeldandi; M S Rao; C A Bradfield; J K Reddy
Journal:  Gene Expr       Date:  2001

Review 5.  Prostate stem cell antigen: a prospective therapeutic and diagnostic target.

Authors:  Adam B Raff; Andrew Gray; W Martin Kast
Journal:  Cancer Lett       Date:  2008-10-05       Impact factor: 8.679

6.  The PPAR alpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha.

Authors:  Qian Yang; Tomokazu Nagano; Yatrik Shah; Connie Cheung; Shinji Ito; Frank J Gonzalez
Journal:  Toxicol Sci       Date:  2007-08-09       Impact factor: 4.849

7.  Stem cell antigen-1 (sca-1) regulates mammary tumor development and cell migration.

Authors:  Torey D Batts; Heather L Machado; Yiqun Zhang; Chad J Creighton; Yi Li; Jeffrey M Rosen
Journal:  PLoS One       Date:  2011-11-29       Impact factor: 3.240

Review 8.  Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens.

Authors:  Harm Westdorp; Annette E Sköld; Berit A Snijer; Sebastian Franik; Sasja F Mulder; Pierre P Major; Ronan Foley; Winald R Gerritsen; I Jolanda M de Vries
Journal:  Front Immunol       Date:  2014-05-06       Impact factor: 7.561

9.  The Quantified Level of Circulating Prostate Stem Cell Antigen mRNA relative to GAPDH Level Is a Clinically Significant Indictor for Predicting Biochemical Recurrence in Prostate Cancer Patients after Radical Prostatectomy.

Authors:  Sung Han Kim; Weon Seo Park; Sang Jin Lee; Moon Kyung Choi; Seung Min Yeon; Jeong Nam Joo; Ara Ko; Eun Sik Lee; Jae Young Joung; Ho Kyung Seo; Jinsoo Chung; Kang Hyun Lee
Journal:  Biomed Res Int       Date:  2015-10-07       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.